Reading the clock signals in a tirzepatide study
LinkedIn caption
📊 Reading the clock signals in a tirzepatide study
Kevin Duffin’s ARDD 2026 presentation examined DNA methylation measurements from a SURMOUNT-5 sub-study. The analysis followed participants over 50 in the tirzepatide arm, comparing blood samples collected at baseline and after 72 weeks of treatment.
💡 Independent analyses by Zymo Research and TruDiagnostic produced broadly consistent findings across several epigenetic clocks. The presentation also described changes in organ-specific clock estimates. Some methylation-based predictions aligned with measured metabolic changes, while others did not, an important test of what these tools can capture during treatment.
The study was small and single-arm, and the clocks were not trained specifically to measure treatment effects. Duffin’s presentation framed these results as hypothesis-generating evidence for further investigation, rather than proof that a clock change establishes clinical rejuvenation.
#ARDD2026 #Biomarkers
X caption
📊 Kevin Duffin examined 72-week tirzepatide data at #ARDD2026: several epigenetic clocks shifted, but some methylation predictions missed. A small, single-arm analysis offering hypotheses to test further. Biomarker shifts need careful interpretation alongside clinical outcomes.
Credit: Michael DeStefano
Copy and paste the caption manually, then attach the downloaded photo. Nothing is published automatically.
